EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer

Sreya Wadud iD, Eleanor J Cheadle, Paul A Sutton

Cancers · 16.04.2026 · 18 (8) · 1261

DOI: 10.3390/cancers18081261 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 16.04.2026. Verfasst von Sreya Wadud und 2 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester M20 4BX, UK. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, The Christie Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment response to neoadjuvant therapy in rectal cancer exhibits a considerable degree of interpatient heterogeneity. Select components of the tumour immune microenvironment have been identified as predictive biomarkers of therapeutic response, for which more evidence is required for future clinical prediction models.

Aim

The research aimed to identify key tumour immune microenvironment biomarkers predictive of the response to neoadjuvant therapy through the systematic appraisal of existing literature.

Methods

A structured search was performed across PubMed, Ovid Embase, and Cochrane databases to retrieve primary studies investigating the association between the tumour immune microenvironment and pathological complete response (pCR) or tumour regression grade (TRG) in patients with rectal cancer. Studies were screened against predefined inclusion and exclusion criteria.

Results

Fifteen studies satisfied the inclusion criteria, with cohorts ranging between 24 and 298 participants with predominantly stage II–III disease. Considerable heterogeneity was observed in both types and methods of quantification of biomarkers. Biomarkers assessed in pretreatment biopsies included tumour-infiltrating lymphocytes (TILs), investigated by subtype (cluster of differentiation (CD)8+, CD4+, forkhead box protein 3+ (FOXP3)) or as a composite measure, as well as programmed death-ligand 1 (PD-L1), PD-1+, natural killer (NK) cells, CD163+, and CD68+. Findings showed that high densities of TILs—particularly the CD8+ subtype—consistently correlated with improved tumour regression. FOXP3+ and CD163+ were inconsistently associated with reduced treatment response. NK cells and CD68+ cells were less frequently investigated and yielded non-significant findings.

Conclusions

CD8+ TILs have the potential to serve as predictive biomarkers of therapeutic response to neoadjuvant treatment in patients with rectal cancer. Inconsistent findings with FOXP3+ Tregs and CD163+ macrophages reinforce the need for their further investigation.

Schlagwörter

Stichwörter der Autor:innen

neoadjuvant therapypathological complete responserectal cancertumour immune microenvironmenttumour regression

Autor:innen und Institutionen

  • Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
  • Targeted Therapy Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester M20 4BX, UK.

ORCID-Profile: Sreya Wadud

Förderung

  • National Institute for Health and Care Research
  • The Christie Charity

Zitieren

APA

Wadud, S., Cheadle, E. J., & Sutton, P. A. (2026). The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer. Cancers, 18(8), 1261. https://doi.org/10.3390/cancers18081261

Vancouver

Wadud S, Cheadle EJ, Sutton PA. The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer. Cancers. 2026;18(8):1261. doi:10.3390/cancers18081261

BibTeX
@article{Wadud2026,
  author = {Wadud, Sreya and Cheadle, Eleanor J and Sutton, Paul A},
  title = {The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1261},
  doi = {10.3390/cancers18081261}
}
Kostenlos starten →